OLAPARIB:一种治疗卵巢癌的PARP抑制剂

Q4 Medicine

Forum of Clinical Oncology Pub Date : 2015-09-01 DOI:10.1515/fco-2015-0014

N. Soupos, K. Laschos, E. Bournakis, E. Kostouros, G. Aravantinos

{"title":"OLAPARIB:一种治疗卵巢癌的PARP抑制剂","authors":"N. Soupos, K. Laschos, E. Bournakis, E. Kostouros, G. Aravantinos","doi":"10.1515/fco-2015-0014","DOIUrl":null,"url":null,"abstract":"Abstract Olaparib is a potent oral inhibitor of PARP 1 & 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations. The aim of this review is to present the results of the various studies which show Olaparib’s efficacy in ovarian cancer","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"6 1","pages":"1 - 7"},"PeriodicalIF":0.0000,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/fco-2015-0014","citationCount":"0","resultStr":"{\"title\":\"OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer\",\"authors\":\"N. Soupos, K. Laschos, E. Bournakis, E. Kostouros, G. Aravantinos\",\"doi\":\"10.1515/fco-2015-0014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Olaparib is a potent oral inhibitor of PARP 1 & 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations. The aim of this review is to present the results of the various studies which show Olaparib’s efficacy in ovarian cancer\",\"PeriodicalId\":38592,\"journal\":{\"name\":\"Forum of Clinical Oncology\",\"volume\":\"6 1\",\"pages\":\"1 - 7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1515/fco-2015-0014\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Forum of Clinical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/fco-2015-0014\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Forum of Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/fco-2015-0014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

奥拉帕尼是一种有效的口服parp1和parp2抑制剂，对多种实体肿瘤患者的种系和/或散发性BRCA突变具有生物活性。这篇综述的目的是介绍各种研究的结果，这些研究表明奥拉帕尼对卵巢癌的疗效

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer

Abstract Olaparib is a potent oral inhibitor of PARP 1 & 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations. The aim of this review is to present the results of the various studies which show Olaparib’s efficacy in ovarian cancer

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Forum of Clinical Oncology Medicine-Oncology

CiteScore

0.50

自引率

0.00%

发文量

审稿时长

6 weeks